A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase ? Clinical Trial to Evaluate Efficacy and Safety of DW2008S in COVID-19 Patients

Start Date24 Sep 2021

Sponsor / Collaborator-

KCT0004125 / RecruitingPhase 1

A dose-block randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of DW2008S after oral administration in healthy male subjects

Start Date29 Jun 2018

Sponsor / Collaborator-

100 Clinical Results associated with DW2008

100 Translational Medicine associated with DW2008

100 Patents (Medical) associated with DW2008

Literatures (Medical) associated with DW2008

01 May 2018·Journal of Cellular and Molecular MedicineQ2 · MEDICINE

DW2008S and its major constituents from Justicia procumbens exert anti‐asthmatic effect via multitargeting activity

Q2 · MEDICINE

ArticleOA

Author: Lee, Hyunyong ; Yoon, Joobyoung ; Youm, Jihyun ; Choi, Youngwoo

AbstractOur previous study revealed that the ethanolic extract of Justicia procumbens ameliorates ovalbumin‐induced airway inflammation and airway hyper‐responsiveness in a mouse model of asthma. However, the mechanism of action of the extract remains unknown. In this study, we prepared DW2008S, an optimized and standardized powder extracted from J. procumbens using anhydrous ethanol, and investigated its anti‐asthmatic effect and mechanism of action. Our results showed that DW2008S contains two major ingredients, justicidin A (JA) and justicidin B (JB), which selectively inhibit T helper 2 (Th2) cell responses in concanavalin A‐activated spleen cells and polarized Th2 cells. Blockade of T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine‐based inhibition motif domains (TIGIT) using a neutralizing antibody also selectively inhibited Th2 cell responses. Furthermore, DW2008S regulated TIGIT expression in the mice and cultured cells. Additionally, DW2008S and JA antagonized human adenosine receptor A3 (A3AR), which mediates mast cell‐dependent inflammation and bronchoconstriction. DW2008S and JB inhibited human phosphodiesterase 4 (PDE4), which is known to cause bronchoconstriction; however, the required concentrations were higher than those needed to affect TIGIT . These findings suggest that DW2008S can potentially ameliorate Th2‐driven airway inflammation and bronchoconstriction through negative regulation of TIGIT and blockade of A3AR and PDE4 activities.

01 Jan 2017·Biological & Pharmaceutical Bulletin

<i>Justicia procumbens</i> Extract (DW2008) Selectively Suppresses Th2 Cytokines in Splenocytes and Ameliorates Ovalbumin-Induced Airway Inflammation in a Mouse Model of Asthma

Article

Author: Yoon, Mi Hee ; Seong, Seungkyoo ; Chang, Hwan Bong ; Choi, Min-Soo ; Jeon, Jihyun ; Youm, Jihyun ; Yoon, Joobyoung ; Na, Kyuheum ; Hwang, Yunha ; Lee, Hyunyong ; Woo, Ji Young

DW2008 is an anhydrous ethanol extract of Justicia procumbens produced by Dong-Wha Pharmaceutical, Inc., Co. as a candidate anti-asthmatic drug. In this study, DW2008 selectively reduced T helper 2 (Th2) cytokines in mouse splenocytes and ameliorated ovalbumin-induced airway inflammation by downregulating pulmonary infiltration of differential inflammatory cells and Th2 cytokines more than a decoction or ethanol extract of J. procumbens did in a mouse asthma model. DW2008 also significantly inhibited airway hyperresponsiveness and reduced the thickness of the airway epithelium. HPLC analysis showed that the major peaks (justicidin A and B) of DW2008 were higher than those of the other extracts. Justicidin A and B significantly suppressed Th2 cytokine levels in mouse spleen cells and exhibited a protective effect in ovalbumin-induced airway inflammation. Our findings indicate that DW2008 effectively inhibits allergic airway inflammatory reactions and airway hyperresponsiveness in a mouse model of asthma, suggesting its potential as an anti-asthmatic agent.

100 Deals associated with DW2008

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Allergic asthma	Phase 1	KR	DONG WHA PHARM Co., Ltd.	30 Jan 2022
Rhinitis	Phase 1	KR	DONG WHA PHARM Co., Ltd.	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

DW2008

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation